Small molecule · Inhibitor of HIV-1 reverse transcriptase · developed by Gilead Sciences
Emtricitabine/tenofovir alafenamide is a fixed-dose combination of two nucleoside analog reverse transcriptase inhibitors, emtricitabine and tenofovir alafenamide. Both act on HIV-1 reverse transcriptase, competing with natural deoxyribonucleosides for incorporation into viral DNA and causing early chain termination. It is studied in HIV-1 infection and pre-exposure prophylaxis of HIV infection.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jul 7, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06337032 | Phase 4 | HIV-1-infection | Recruiting | GILD |
| NCT04994509 | Phase 3 | Pre-Exposure Prophylaxis of HIV Infection | Active not recruiting | GILD |
| NCT07473778 | N/A | HIV Infections | Recruiting | GILD |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
HIV InfectionsHIV-1-infectionPre-Exposure Prophylaxis of HIV Infection
Updated Oct 25, 2026. Something wrong or missing? Report it on the GILD page.
See GILD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
GILD catalysts and pipeline →